Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

New Approaches in Hepatocellular Carcinoma

May 28th 2015

Genetic Testing and Second-Line Treatments in HCC

May 28th 2015

Administering Sorafenib in Hepatocellular Carcinoma

May 28th 2015

Multidisciplinary Systemic Therapy in HCC

May 28th 2015

Embolization Therapy for Unresectable HCC

May 28th 2015

Transplantation Versus Resection in Patients With HCC

May 28th 2015

The Impact of Cirrhosis on Treating HCC

May 28th 2015

HCC: Evolving Screening and Surveillance

May 28th 2015

Tabernero Discusses Novel Antibody Mixture Sym004 and Emerging Trends in Colorectal Cancer

May 18th 2015

Josep Tabernero, MD, PhD, discusses the potential of the antibody mixture Sym004 in mCRC, as well as other emerging trends in the management of colorectal cancer.

Fuchs Discusses Impact of Ramucirumab Approval in mCRC

May 15th 2015

Charles S. Fuchs, MD, discusses the impact of the approval of ramucirumab in metastatic colorectal cancer and what further research is needed for the optimal utilization of the VEGFR-2 inhibitor.

TAS-102 Improves Survival in Refractory mCRC

May 15th 2015

Treatment with the oral nucleoside TAS-102 (tipiracil hydrochloride) demonstrated a significant improvement in overall survival compared with placebo for patients with refractory metastatic colorectal cancer.

Initiative Seeks to Advance Molecular Understanding of Pancreatic Cancer

May 7th 2015

A partnership between the Pancreatic Cancer Action Network and Perthera, a self-described "concierge" for molecular diagnostic testing, is aiming to give patients with this hard-to-treat cancer the ability to determine the best course of treatment.

Dr. Andrew Chan on Aspirin's Link to Reduced Cancer Risk

May 4th 2015

Andrew T. Chan, MD, MPH, a research fellow in the Department of Nutrition at the Harvard School of Public Health, discusses the impact of aspirin of cancer risk.

Ramucirumab Approval Expanded, Breakthrough Designation for Crizotinib, and More

May 2nd 2015

Dr. Daniel Von Hoff on Combination Treatments for Late Stage Pancreatic Cancer

April 27th 2015

Daniel Von Hoff, MD, the Physician-in-Chief and Director of Translational Research at the Translational Genomics Research Institute (TGen) and a special consult with Baylor University College of Medicine, discuses combination treatments for pancreatic cancer.

FDA Approval Sought for MM-398 in Advanced Pancreatic Cancer

April 27th 2015

A new drug application has been submitted for MM-398 in combination with 5-fluorouracil and leucovorin for patients with metastatic pancreatic cancer following prior treatment with a gemcitabine-based therapy.

FDA Approves Second-Line Ramucirumab for mCRC

April 24th 2015

The FDA has approved second-line ramucirumab in combination with FOLFIRI as a treatment for patients with metastatic colorectal cancer (mCRC) following progression an upfront bevacizumab-containing regimen.

Long-term Aspirin Use Decreases Risk of GI Cancers, Especially Colorectal

April 20th 2015

A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.

Oral Fluoropyrimidine TAS-102 in Refractory mCRC

April 16th 2015

Use of Regorafenib in Refractory mCRC

April 16th 2015